Gene Therapy: Bluebird’s Beti-Cel Sails Through US Panel Review On Strength of ‘Impressive’ Efficacy

 
• By Sue Sutter

Treatment is a potential game-changer for patients with transfusion-dependent beta-thalassemia, committee members said; panel was hesitant to extrapolate the hematological malignancies seen with bluebird’s other lentiviral vector programs to beti-cel.  

Sailboat
Bluebird found smooth sailing for its beta-thalassemia gene therapy at a US FDA meeting. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers